Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma Intervention: Drug: Pembrolizumab Sponsors: Abramson Cancer Center of the University of Pennsylvania; Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Merkel Cell Carcinoma | Neoadjuvant Therapy | Research | University of Pennsylvania